Articles tagged with Insulin
Researchers found that liraglutide improves associative learning in people with obesity by restoring brain activity to normal-weight levels. The study showed that participants with obesity had reduced ability to associate sensory stimuli and decreased brain activity compared to those with normal weight.
Researchers aim to investigate the link between gut microbes and Type 1 diabetes. Emrah Altindis's lab seeks to understand how a protein found in certain bacteria may trigger the onset of T1D.
A recent study found that patients with type 1 diabetes using insulin pumps for extended periods do not exhibit significantly more pathology in their skin compared to short-term users. Despite this, researchers still struggle to understand the underlying causes of skin damage and inflammation at infusion sites.
A new study found that snacking on high-quality foods can improve blood fat and insulin responses, while late-night snacking may have unfavorable effects. The researchers analyzed data from over 1,000 people in the UK and found no association between snack frequency or calories consumed and health measures.
Researchers at UC Berkeley discovered that deep-sleep brain waves can regulate the body's sensitivity to insulin, improving blood sugar control. The study found that synchronized brain waves during deep sleep predict next-day glucose control, even after controlling for other factors.
A study published in Nature Communications reveals the controlled release of mucins and insulin by cells, with tetraspanin-8 acting as a gatekeeper. The regulated secretion is biphasic, involving rapid and slower releases of granules, which can be targeted to reset deregulated mucin and insulin secretion.
A recent meta-analysis of 29 studies found that intranasal insulin treatment can boost cognition in individuals with mild cognitive impairment or Alzheimer's Disease. The analysis suggests potential benefits for this treatment approach, which may be worth further investigation.
Once-weekly Icodec demonstrated superior HbA1c reduction compared to once-daily Degludec after 26 weeks, but no difference was found in weight change. However, Icodec showed a higher rate of combined level two or three hypoglycemic events
Researchers have found a hidden mechanism connecting cancer and diabetes, where cancer cells don't respond well to insulin, leading to faster cancer growth. Insulin resistance can also cause muscle loss and strength decline in cancer patients.
A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.
A plant-based, oral delivery of proinsulin regulated blood sugar within 15 minutes similar to naturally secreted insulin in diabetic mice. This method eliminates the need for expensive laboratory equipment and results in a shelf-stable product, making it more affordable and accessible.
A study found that even insured patients with diabetes use crowdfunding platforms like GoFundMe to cover excess medical expenses, including uncovered co-pays and life-saving care. Researchers urge policymakers to consider these needs when developing affordable diabetes care policies.
A study of over 55,000 people identified new genetic variants associated with insulin resistance after eating, which may help inform future treatments of type 2 diabetes. The discovery highlights the importance of understanding how glucose regulation works in the body, particularly in the fed state.
Researchers have discovered molecules in 3,000 diabetic patients that could help predict and monitor disease progression. The study identified 20 biomarkers associated with rapid disease progression, including a protein called NogoR.
Researchers at Weill Cornell Medicine have successfully converted human stomach stem cells into insulin-secreting cells, offering a promising approach to treating type 1 and severe type 2 diabetes. The transplants reversed disease signs in mouse models, suggesting good durability.
Researchers have developed an algorithm that accounts for individual patient differences and validated a pump control algorithm that does not require meal announcement. This innovation simplifies the control problem, reduces delays, and increases the accuracy of insulin delivery, making diabetes management less burdensome for patients.
Rice University scientists developed a screening technique to identify high-performing biomaterials for encapsulating insulin-secreting cells, providing long-term blood sugar level control in diabetic mice. The study's findings have the potential to open the door to a more sustainable and self-regulating way to treat Type 1 diabetes.
A new study has identified a metabolic enzyme called FBP1 that acts as a safety valve to prevent insulin shock. Researchers found that FBP1 inhibits protein kinase AKT, which is the primary conduit of insulin activity, and developed a peptide derived from FBP1 that can reverse insulin resistance and restore normal glycemic control.
A recent analysis of three clinical trials found that the UVA-developed artificial pancreas improved blood sugar control by 13 percentage points and decreased hemoglobin A1c levels. The device spent an average of 2.8 more hours per day in target blood sugar range, benefiting both kids and adults with diabetes.
Researchers at RMIT University have designed a new oral capsule that can deliver insulin and other protein drugs in a pain-free manner. The technology has shown promising results in pre-clinical studies, with good absorption rates for slow-acting insulin and potential for dosing over specific time periods.
Researchers have developed a novel insulin formulation that can be switched on by glucose, offering improved regulation of blood sugar levels in patients with type 1 diabetes. The new formulation uses biocompatible lipid nanoparticles and achieves precise control of insulin release in response to fluctuations in blood sugar.
Researchers at the University of Gothenburg discovered that insulin can be stored at room temperature for four weeks, quadrupling its previous storage period. This finding has significant implications for global health, particularly in developing countries where insulin is often in short supply and expensive.
A team of researchers at ETH Zurich has created an implantable fuel cell that uses excess blood sugar to generate electrical energy. The device powers artificial beta cells that produce insulin, effectively regulating blood glucose levels.
Two new subtypes of insulin-producing beta cells, ß <sub> HI </sub> and ß <sub> LO </sub>, have been identified with distinct characteristics. The study suggests epigenetic dosage as a driving force behind the decision of ß cells to become these subtypes, offering a new target for potential diabetes treatments.
A new study by Weill Cornell Medicine investigators found four distinct types of beta cells in the pancreas, with cluster 1 beta cells producing more insulin than others and appearing better able to metabolize sugar. The loss of these high-functioning beta cells may contribute to type 2 diabetes development.
Dr. David McDougal's research project aims to find better therapies to prevent hypoglycemic episodes in people with type 1 diabetes, focusing on the role of leptin in regulating blood sugar responses. The grant-funded study seeks to identify novel treatments for preventing low blood glucose in these patients.
A study published in Communications Biology reveals that a large portion of an insulin dose may not be effective, providing a tool for developing more precise medications. The discovery could lead to improved treatment outcomes for millions of people worldwide.
A new clinical trial has shown safety and tolerability of oral GABA and reduced serum glucagon levels in children with recent onset Type 1 diabetes. The study focused on the potential of GABA and GAD to preserve insulin-secreting beta cells and attenuate excessive glucagon release.
Researchers reveal Akt2's role in insulin-regulated metabolism, initiating energy production and nucleic acid synthesis. The study provides new insights into metabolic disorders like diabetes, paving the way for targeted therapeutics.
A recent study published in the Journal of Clinical Investigation found that PAX5 is strongly associated with impaired insulin secretion in type 2 diabetes. The research team identified 94 previously known genes and discovered many new genes differently expressed in individuals with type 2 diabetes.
A survey of primary care clinicians revealed that 44% of patients experience cost-related insulin underuse, with those experiencing poor diabetes control not being more likely to report underuse. Clinicians can address this issue by using empathy to discuss cost barriers and increase the likelihood of changing insulin prescriptions.
Researchers at the University of Cambridge developed an artificial pancreas that can help maintain healthy glucose levels in type 2 diabetes patients. The device doubled the time spent in the target range for glucose and halved the time spent with high glucose levels, reducing average glucose levels and glycated haemoglobin levels.
Researchers have developed an orally administered tablet powered by chemical micromotors that deliver insulin to the colon, reducing blood glucose levels for over five hours. The mini-tablets protected from stomach acid and used hydrogen gas bubbles as micromotors to propel insulin into the bloodstream.
Researchers discovered that physical activity suppresses insulin-producing cells in fruit flies, allowing for efficient energy replenishment. This finding has implications for human health, as reduced insulin activity is linked to healthy ageing and longevity.
Researchers found that people with higher levels of Coprococcus tended to have higher insulin sensitivity, while those with Flavonifractor had lower insulin sensitivity. The study aimed to understand the relationship between microbiome composition and diabetes development.
A wafer-thin device called NICHE has been developed to treat Type 1 diabetes by delivering islet cells and immunotherapy directly into the body. The device restored healthy glucose levels and eliminated symptoms for over 150 days, avoiding severe adverse effects of anti-rejection therapy.
Over three decades, glycemic control stagnated among US adults with diabetes, exacerbating racial and ethnic disparities. Improved insulin access may optimize glycemic control and reduce disparities in this population.
WEHI researchers have visualized how a non-insulin molecule can mimic the role of insulin, opening new avenues for an oral insulin pill. The study confirms alternative molecules can be used to turn on blood glucose uptake, bypassing insulin needs.
Insulin pump use has grown over two decades but disparities persist among racial, ethnic, and socioeconomic groups. Youth from lower-income backgrounds and minority groups are less likely to use insulin pumps.
A study published in the Hypertension journal suggests that bromocriptine, a Parkinson's disease medication, may help prevent heart disease in youth with Type 1 diabetes. The research found that teens with Type 1 diabetes who took bromocriptine had lower blood pressure and less stiff arteries after one month of treatment.
Researchers found that individuals with CYP8B1 loss-of-function mutations have improved insulin sensitivity and better glucose regulation, reducing the risk of developing Type 2 diabetes. The study suggests a potential new treatment approach using bile acid modulators to target this gene.
A new study published in the Journal of Clinical Endocrinology & Metabolism reveals that pancreas transplantation can provide up to 90% of recipients with diabetes freedom from insulin therapy and glucose monitoring. Despite high success rates, transplant numbers have declined due to lack of consensus criteria, education, and resource ...
A novel HNF1A gene variant has been found to cause monogenic diabetes, affecting almost seven percent of all cases in Greenland. This discovery may pave the way for precision treatment using tablet therapy with sulphonylurea, offering a simpler and cheaper alternative to insulin.
A randomized controlled trial found that both total ankle replacement and ankle fusion improve quality of life and have similar clinical scores in patients with end-stage ankle osteoarthritis. However, TAR is associated with greater wound-healing complications and nerve injuries, while AF is linked to more blood clots and nonunion of t...
Researchers at the University of Helsinki have identified a promising drug candidate, TYK2 inhibitor, for preventing type 1 diabetes. The study found that inhibiting TYK2 expression reduces the destruction of pancreatic beta cells, but may also reduce beta cell production in earlier stages.
A team at the University of Exeter has found genetic changes in a region that controls the activity of the genome, turning on or off genes, which led to the discovery of the cause of Congenital Hyperinsulinism. This breakthrough could unlock new causes of rare diseases and pave the way for improved treatments.
Researchers at Osaka University identified T-cadherin as a factor that feeds back a lack of insulin to pancreatic β cells, inducing their proliferation. This finding suggests a potential new treatment for diabetes by targeting T-cadherin.
A large clinical trial found that administering steroids during infant heart surgery did not improve post-operative outcomes compared to placebo. However, secondary analysis revealed a small net benefit for some infants, with lower odds of bleeding requiring another operation.
A new study from the University of Missouri School of Medicine found that short-term exposure to reduced physical activity and increased sugar consumption disrupts insulin response in blood vessels, with men more prone to vascular insulin resistance. In contrast, young women are protected against this condition.
A study found that the HASTER lncRNA promoter regulates the activity of the HNF1A gene, which causes diabetes. This discovery paves the way for new therapeutic strategies by manipulating this regulatory element.
A study found that 16.5% of American adults with diabetes ration their insulin, with younger adults and the uninsured being most affected. Insulin rationing is often linked to cost concerns, with many patients delaying purchases or taking less insulin than needed.
Researchers identified protein levels that were higher or lower than normal in tissues from individuals at different stages of type 2 diabetes. The study found a correlation between metabolic pathway disturbances and disease progression, suggesting new potential causal mechanisms for the disease.
A new clinical trial found that the bionic pancreas device was more effective at maintaining blood glucose levels within normal range than standard-of-care management among people with type 1 diabetes. The device requires minimal user input and provides more automation, resulting in improved glycemic control.
Researchers at Brigham and Women's Hospital and MIT have developed RoboCap, a robotic capsule that delivers drugs to the gut by clearing mucus and churning to enhance absorption. In preclinical models, RoboCap increased drug permeability by over 10-fold for insulin and vancomycin.
A new drug capsule developed at MIT may be able to replace injections for biologic drugs by tunneling through the mucus barrier in the small intestine. The capsule's robotic cap spins and displaces mucus, allowing drugs to pass into cells lining the intestine.
A bionic pancreas, which automatically delivers insulin based on blood glucose levels, was more effective than standard care at maintaining normal blood sugar levels. The study, funded by NIDDK and conducted at Nemours Children's Health, Jacksonville, found the device to require less user input and provide more automation.
Researchers found that knocking out TXNIP in alpha cells improves diabetes-associated hyperglycemia and hyperglucagonemia. This discovery suggests a new potential treatment for Type 1 diabetes.
A new study found that placing a monthly cap on out-of-pocket costs for commercially insured patients could lower their highest monthly healthcare bills by 50-60%. A $500 monthly limit would affect about 25% of enrollees and reduce in-network OOP costs over a year by 46%, while a $250 limit would show a 51% reduction.
A new study estimates that up to 17.5 million people worldwide will live with Type 1 Diabetes by 2040, with the highest burden in low- and middle-income countries. The modeling study predicts a significant increase in global deaths due to T1D, highlighting the need for improved surveillance, diagnosis, and care.
The need to reduce diabetes care product waste is a pressing issue, with disposable devices generating enormous amounts of plastic. Experts, including Professor Lutz Heinemann, are exploring strategies to increase recycling and sustainability in the industry.